Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

NCT05891119 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DIETARY_SUPPLEMENT: Caffeine
DRUG: Metoprolol
DRUG: Midazolam
DRUG: Warfarin
DIETARY_SUPPLEMENT: Vitamin K
DRUG: Omeprazole
DRUG: Rocatinlimab

Sponsor

Amgen